Background: An imbalance between renal damaging molecules and nephroprotective factors contributes to the development and progression of kidney diseases.
factors and pathways that drive the progression of CKD with the ultimate aim to identify targets for intervention. For example, landmark studies by Brenner et al identified the activity of the renin-angiotensin system as a key player in the loss of GFR, and consequently, agents that block the system have successfully been introduced in clinical practice. [4] [5] [6] Other features of progressive CKD are inflammation and fibrosis, and the search for appropriate "anti-inflammatory and antifibrotic" drugs continues. 7 Research also identified acute kidney injury (AKI) as risk factor for the development of CKD, which also affects injury and repair mechanisms. 8, 9 With the rise of "omics" techniques, it has become evident that on a molecular level, CKD is even much more complex with multiple processes interacting. 10 Furthermore, intrinsic protective pathways have been identified as well counterbalancing deleterious developments, and probably the rate of progression of CKD is ultimately determined by the balance between injury and repair. Adrenomedullin, for example, was recently shown to prevent tubular damage and apoptosis in vitro. 11 Sirtuin 1 (SIRT1) was reported to counterbalance inflammatory signalling in renal cells via NFKB signalling. 12, 13 Clusterin (CLU) is discussed as molecule exerting its renoprotective properties by counteracting hypoxia/ischaemia-mediated injury via activation of prosurvival autophagy. 14 Next to these protein coding genes, also microRNAs as well as extracellular vesicles may play an important role. 15, 16 If we accept this "balance" concept of the pathogenesis of CKD progression, we consequently should not only focus on experiments that interfere with damaging pathways but also explore possibilities to foster intrinsic, nephroprotective processes. In this review, we systematically mined the scientific literature for proteins holding evidence serving as renoprotective factors and consecutively analysed this set of molecules regarding functional involvement, tissue-specific expression as well as subcellular location. The mechanisms and factors are also discussed in the light of potential novel treatment options. This consolidated set of renoprotective factors could also serve as a starting point for further analyses using omics data in the context of renal disease to identify novel markers, targets or therapeutic options.
| GENERATING A SET OF RENOPROTECTIVE FACTORS
We used the GeneRIF (Gene Reference into Function) data set available at NCBI to generate a set of renoprotective factors. A GeneRIF is a concise phrase describing the function of a particular gene. A GeneRIF is always linked to a publication indexed in PubMed and is associated with one or more genes with a valid NCBI Entrez Gene ID. GeneRIFs are either generated by authors of a respective publication via a dedicated submission form or created by Medical Subject Heading indexers of the National Library of Medicine. 17 We downloaded the full set of GeneRIFs from NCBI's FTP site on the 17th of June 2017. GeneRIFs holding the following terms were extracted: "protective" or "protecting" or "protection" or "regenerative" or "regenerating" or "regeneration" in combination with one of the following phrases: "kidney" or "renal" or "nephro." A total of 416 GeneRIFs and 536 GeneRIF-gene pairs were identified covering 404 unique genes based on their NCBI Entrez Gene ID linking back to 407 publications (see Figure 1) .
With a large number of functional experiments conducted in animal model systems, a significant fraction of GeneRIF-gene pairs also consisted of model system genes making it necessary to map those genes to their human homologs. The Bioconductor R package biomaRt was used for homology mapping using data from the Ensembl BioMart. A total of 308 unique human genes remained in the GeneRIF set after homology mapping. We manually investigated the GeneRIF set and excluded GeneRIF-gene pairs to end up with a clean set of renoprotective factors as described in the following. Redundant GeneRIF-gene pairs resulting from homology mapping as well as GeneRIFgene pairs with no corresponding homologous human gene were excluded. In a second step, we excluded GeneRIFgene pairs with nonprotein coding genes as the focus of this study was on renoprotective protein factors. We next excluded false-positive associations such as "Quercetin has renal protective effects partly through reducing NF-kappaB p65 expression in diabetic rats" where the renoprotective effect is attributable to the compound by reducing expression levels of the respective gene mentioned in the GeneRIF. We in this step also excluded GeneRIF-gene pairs stating that no significant renoprotective effect was obtained by a certain factor. In a final cleaning step, we removed GeneRIF-gene pairs reporting on the impact of genetic variations of a certain gene on renoprotection. The final set for further analyses consisted of 299 GeneRIFgene pairs based on 268 individual GeneRIFs holding 193 unique human genes linking back to 263 publications. The full list of GeneRIF-gene pairs is available in Table S1 .
enriched cellular compartments, tissues, as well as biological processes based on the set of 193 identified renoprotective factors. 18 For analysis of cellular compartments and biological processes, the gene ontology cellular components (GO-cc) and gene ontology biological processes (GO-bp) vocabulary was used. NCBI's expressed sequence tag (EST) counts were used as a basis for identification of enriched tissues based on the set of renoprotective factors. The significance level was set to <0.05 after Bonferroni's correction for multiple testing for each of the enrichment analyses. Enriched subcellular locations and tissue terms were downloaded from the DAVID analysis portal and visualized in Figure 2 . The largest fraction of renoprotective factors is either located in the plasma membrane or secreted into extracellular space. This is interesting as consequently therapy could be achieved easier.
Next to the enrichment for expression in kidney, which was not unexpected due to the selection process, there was an enrichment of expression in connective tissue as well as pancreas (see Figure 2) . Also, the enrichment of molecules showing higher expression in connective tissue is not too surprising with modifications in extracellular matrix being one of the hallmarks of progressive chronic kidney disease. The enrichment of molecules showing higher expression in pancreas might be explained by the fact that certain molecules involved in glucose metabolism are in the list of renoprotective factors such as glucagon or the glucagonlike peptide 1 receptor (GLP1R) being highly expressed in pancreas.
A total of 55 enriched biological processes were identified, which were forwarded to the REViGO tool for reducing and visualizing the set of enriched GO terms. 19 REViGO removes redundant GO terms and groups GO terms based on the semantic similarity. REViGO was run with the default parameters (SimRel as a semantic similarity measure with the allowed similarity set to medium) to assess GO term similarity with the Homo sapiens GO database as underlying data set. The resulting network of enriched GO biological process terms is displayed in Figure 3 .
The grouped GO biological processes were further categorized into the broader mechanistic themes of "cellular response," "inflammatory response," "cell proliferation," "apoptosis," "signalling" and "blood pressure regulation" that became apparent when inspecting the clusters of GO biological process terms. These mechanistic themes are discussed in more detail in subsequent sections of this article, but before doing so, we were interested in direct proteinprotein interactions of renoprotective factors to investigate how these factors potentially influence each other.
| PROTEIN-PROTEIN INTERACTION ANALYSIS
We constructed a protein-protein interaction network based on the interaction data from BioGRID, Reactome and IntAct. We only considered interactions between members of the set of 193 renoprotective factors and visualized the resulting interactions with CYTOSCAPE version 3.5.1 (see Figure 4) . The resulting interaction network consisted of 145 proteins and 425 interactions. We determined the node degree of each protein, that is the number of direct interaction partners, in the network. The transcription factor TP53 had the largest number of neighbours followed by proopiomelanocortin alpha (POMC), also known as ACTH or corticotropin, and the heat-shock protein family A (Hsp70) member 4 (HSPA4).
We further generated a ranking of renoprotective factors based on the sum rank of the GeneRIF count rank as well as the rank based on the number of direct protein neighbours in the protein-protein interaction network. The top 25 renoprotective factors based on the sum rank are listed in Table 1 .
In the following sections on pathways and mechanisms, particular emphasis is on highly ranked renoprotective factors as listed in Table 1 .
| AFFECTED PATHWAYS AND MECHANISMS
AKI and renal failure are characterized by the death of renal tubular cells via apoptosis or necrosis, vascular dysfunction and inflammation induced by renal ischaemic reperfusion, nephrotoxicity or sepsis. An increase in cytokines and chemokines is observed during inflammatory response in AKI but also in the context of CKD due to F I G U R E 4 Protein-protein interaction network of renoprotective factors. Protein-protein interaction network consisting of those renoprotective factors with at least one protein-protein interaction to at least one other protein from the set of 193 renoprotective factors. Factors with clinical trial evidence in the context of kidney disease or diabetes are labelled in red. Node colour coding reflects the number of neighbours (node degree) in the interaction network with darker colours indicating a higher number of neighbours continuous protein overload. Inflammation and vascular dysfunction may lead to derangements in extracellular matrix and subsequent interstitial fibrosis, one of the hallmarks of CKD. Hypoxia is another process contributing to the extracellular matrix production as well as epithelialmesenchymal transdifferentiation and is thought to play a role even early on in the development of kidney disease. Complement activation in tubular cells may contribute to the production of reactive oxygen species and further enhance proinflammatory mechanisms. Persistent oxidative stress in turn is linked to stress-induced increase of apoptotic processes.
The gene with the largest number of renoprotective GeneRIFs based on our analysis was heme oxygenase 1 (HMOX1), followed by the transcription factor NFE2L2, also known as NRF2. HMOX1 protects cells against oxidative injury and cellular stress, which was in particular evident in human renal proximal tubular cells demonstrated in in vitro as well as in in vivo experiments. [20] [21] [22] Next to the protective role in the context of acute kidney injury, 23, 24 HMOX1 was reported to have positive impact on renal graft survival after renal transplantation. 25, 26 The transcription factor NRF2 is another molecule reported to be involved in counterbalancing oxidative stress via activation of antioxidant proteins, among them, next to the above-mentioned HMOX1, catalase (CAT) and superoxide dismutase 1 (SOD1) being also part of the renoprotective factor list. An extensive review on the role of NRF2 in renoprotection was previously published by Choi et al 27 also discussing the anti-inflammatory properties of NRF2 via blocking of NFKB signalling. Despite the fact that bardoxolone methyl, a NRF2 agonist, showed promising results in patients with chronic kidney disease in a phase II study, development had to be stopped due to an increased rate of adverse effects in a subsequent phase III study. 28, 29 Newly initiated clinical trials will ultimately MET MET proto-oncogene, receptor tyrosine kinase C-MET 2 9
Listing of the top 25 renoprotective factors based on the sum rank of GeneRIF count and node degree. Next to the official gene symbol and the gene name, also commonly used aliases are provided.
show whether the benefit/risk ratio for bardoxolone methyl is positive in selected patient cohorts. 30 Resveratrol is a natural compound capable of activating NRF2 and might thus depict another treatment option to counterbalance kidney damage. 27 The positive effect of resveratrol on the renoprotective factor sirtuin 1 (SIRT1) was reported in a rat model of diabetic nephropathy by Tikoo et al. 31 SIRT1 is the topranked factor based on the number of scientific reports as well as protein interactions in our data set with six GeneRIFs reporting on the renoprotective properties of SIRT1 and 15 interacting protein neighbours in the interaction network. SIRT1 protects against apoptosis via activation of catalase with a number of publications reporting about its nephroprotective effect making it another promising therapy target in the area of kidney disease and diabetes mellitus. 32 6 | APOPTOSIS AND OXIDATIVE
STRESS
Other molecules next to SIRT1 protecting from apoptosis in renal cells are CDKN1A and glucagon (GCG). CDKN1A was shown to protect renal cells from cisplatininduced apoptosis via inhibition of CDK2 activity. 33 Katagiri et al 34 reported on the antiapoptotic effect of glucagonlike peptide 1 (GLP-1) in a mouse model of cisplatininduced acute kidney injury. Binding of CXCL12, also known as stromal cell-derived factor 1 (SDF-1), to the chemokine receptor 4 (CXCR4) represents another mechanism counteracting apoptosis of renal cells. 35 CXCL12 is in addition elevated after ischaemic reperfusion injury protecting tubular epithelial cells as shown by Stokman et al 36 in animal models using antisense oligonucleotides against CXCL12. CCR7 is linked to CXCR4 and CXCL12 in the protein-protein interaction network and also reported to be involved in antiapoptotic processes in mesangial cells. 37 It is due to the presence of survival factors that apoptosis is not initiated in normal cells with a misbalance of proapoptotic and antiapoptotic molecules based on external stimuli triggering apoptosis in most cases.
| Cellular response mechanisms
A number of biological processes related to cellular response to certain stimuli were enriched in renoprotective factors, among them terms such as "response to hypoxia," "response to drug," "response to heat," "response to hydrogen peroxide" or "cellular response to lipopolysaccharide."
The most enriched biological process in this category was response to hypoxia with the hypoxia-inducible factor 1A (HIF1A) being one of the prime factors in counterbalancing ischaemic reperfusion injury. 38 The direct targets of HIF1A, namely the vascular endothelial growth factor (VEGFA) and adrenomedullin (ADM), were also among the top-ranked renoprotective factors. A deregulation in the hypoxia response and VEGFA axis was previously reported by Rudnicki et al 39 to play a role in progressive chronic kidney disease. HIF1A upregulation along with HMOX1 activation after donor preconditioning with fenoldopam was shown to have positive effects on renal function in a rat kidney transplantation model. 40 VEGFA in contrast is of particular importance for endothelial regeneration after renal injury as reported by Ohara et al. 41 Inhibition of HIF1A was also shown to induce expression of TGFB1, MMP13 and collagen I next to enhancing expression of inflammatory molecules IL1B, TNF, CCL2 (MCP-1) and VCAM1. Part of these effects could be attributed to a downregulation of miR-127-3p. 42 Lipocalin 2 (LCN2), also known as NGAL, is one of the most discussed and analysed molecular markers in the field of acute as well as chronic kidney disease. LCN2 was also shown to induce renal cell regeneration and thus serves as marker indicating renal cell damage as well as graft function in renal transplantation. 43, 44 The reader is referred to a review on ischaemic kidney injury and mechanisms of tissue repair by El Sabbahy and Vaidya, who discuss mechanisms of ischaemic injury and repair in acute and chronic kidney diseases. 45 A set of heat-shock proteins (HSPA4, HSPA5, HSPA1A, HSPA1B, HSPB1, HSPA2, HSPB2) could be found in our list or renoprotective factors with documented positive effects not only on ischaemic reperfusion injury but also on drug-induced kidney injury. [46] [47] [48] Other molecules with three or more of the cellular response GO terms assigned are the retinoic acid receptor alpha (RARA), cyclin D1 (CCND1), tyrosine hydroxylase (TH), the translocator protein (TSPO), the thromboxane A2 receptor (TBXA2R), C-X-C motif chemokine ligand 12 (CXCL12), ETS proto-oncogene 1 (ETS1), as well as the before-mentioned molecules CAT, SOD1 and LCN2.
| Inflammatory response
Short-term inflammation may be considered as protective response to renal damage but can lead to progression of disease if developing into a long-lasting process. 49 In particular, macrophages and regulatory T cells play key roles in anti-inflammatory responses. 50 A number of proinflammatory molecules such as CCL2 (MCP-1) or the tumour necrosis factor receptors 1 and 2 (TNFRSF1A, TNFRSF1B) have also been evaluated as biomarkers for diabetic nephropathy disease progression. 51 IL10 was found to be essential for downregulation of proinflammatory chemokines such as CCL2 (MCP-1) or CCL5 (RANTES) in a mouse model. 57 In addition, a higher degree of fibrosis was observed in animal with IL10 deficiency.
Inflammation is considered as a relevant mechanism in the development of AKI as well as in the progression of CKD. A number of compounds have been studied for their anti-inflammatory properties and even compounds with a different primary mechanism of action such as statins with their lipid-lowering capacity have been investigated in the context of anti-inflammatory mechanisms. 58 
| Cell proliferation and signalling
Members from the category of growth factors in our list include VEGFA, HGF (hepatocyte growth factor), as well as the insulin growth factor 1 (IGF1) and its receptor IGFR1 that have been reported to counterbalance renal injury shortly after an acute insult. 59 Endogenous HGF was also shown to have positive impact on renal tissue in the context of chronic kidney disease. 60 In particular, the positive impact on podocytes was demonstrated in a mouse model by Dai et al. HGF reduced the amount of podocyte apoptosis and also led to reduced proteinuria in the studied animals. 61 Evidence for HGF as therapeutic option is also available with Flaquer et al 62 reporting on the positive effect of HGF in a diabetic nephropathy mouse model via gene therapy of HGF alone or in combination with the colony-stimulating factor 1 (CSF1). CSF1, which controls macrophage proliferation and differentiation, was shown to induce expression of IGF1 and other anti-inflammatory proteins in a mouse model of ischaemic reperfusion injury, thus promoting endogenous repair and counterbalancing inflammation. 63 Among the renoprotective cell receptors were also the adenosine receptors A1, A2A and A2B (ADORA1, ADORA2A and ADORA2B), which were mainly discussed in the context of protection from renal ischaemic reperfusion injury. [64] [65] [66] Sphingosine kinase 1 (SPHK1) and netrin 1 (NTN1) are two molecules worth mentioning in the context of adenosine receptors. SPHK1 was shown to be essential for the renoprotective effect of ADORA1A as reported by Park et al 64 when testing ADORA1 agonists in mouse models of ischaemic reperfusion injury. NTN1, on the other hand, was reported to attenuate albuminuria and improve histological lesions in diabetic kidney disease in vivo but only with an intact adenosine A2B receptor present. 67 The Wnt/beta-catenin (CTNNB1) signalling pathway leads to cell proliferation and cell survival via activation of molecules such as cyclin D (CCND1) or survivin (BIRC5) and blocks apoptosis via activation of AKT1 in epithelial cells in acute kidney injury. Recent reports also pinpoint to a protective role of the Wnt/beta-catenin signalling pathway in the context of chronic kidney disease with other studies, however, reporting on the profibrotic impact of this signalling pathway. 68 In general, growth factor-mediated signalling was shown to be important for survival and proliferation of renal tubular cells during phases of recovery and repair after injury. On the other hand, reports exist on the detrimental effects of growth factors on renal cell function with growth factor inhibitors also being investigated as antifibrotic therapy. 69 It might thus depend on the timing and duration of cell proliferation pathway activation whether injury or repair is triggered in the end.
| Blood pressure regulation
Factors with renoprotective potential involved in blood pressure regulation are among others the bradykinin receptor B1 (BDKRB1), kininogen 1 (KNG1) or ADM. BDKRB1 was shown to be upregulated in a rat model of high blood pressure supposed to counterbalance profibrotic stimuli via increase of nitric oxide generation as well as inhibition of TGFB1 expression. 70 The kallikrein-kinin system in hypertension and organ damage in the context of its positive impact on processes of oxidative stress, apoptosis, inflammation as well as hypertrophy and fibrosis was recently highlighted in a review by Chao et al. 71 ADM has a number of functions, among others regulation of hormone secretion and promotion of angiogenesis, but also vasodilation, and was also shown to counterbalance tubular damage in animal models. 11 The two neuropeptides adenylate cyclase-activating polypeptide 1 (ADCYAP1) and calcitonin-related polypeptide alpha (CALCA) which were highly ranked in our list of renoprotective factors and linked on the level of protein-protein interactions were shown to have vasodilatory potential. CALCA was reported to protect kidney tissue from damage induced by hypertension with ADCYAP1 counteracting ischaemic reperfusion injury. are still studied in many clinical trials in the context of kidney disease and renal failure, there are a number of clinical studies focusing on the renoprotective factors itself as therapeutic options as listed in Table 2 . The hepatocyte growth factor is currently investigated in a phase II clinical trial on acute kidney injury and a phase III clinical trial in the context of renal transplantation. Both studies are currently recruiting patients with the phase II AKI study focusing on patients at risk of developing AKI after cardiac surgical procedures and the phase III study recruiting transplant patients of increased risk of developing delayed graft function (DGF) after receiving a renal transplant from a deceased donor (NCT02474667). Primary outcome measure of the phase II AKI study is the percentage increase in serum creatinine above baseline, whereas the severity of DGF assessed based on the number of days a transplant recipient has to stay on dialysis treatment will be evaluated in the phase III transplant study. Another renoprotective factor studied in the context of renal transplantation is HMOX1 with an available phase III clinical trial investigating the potential to reduce ischaemic reperfusion injury after renal transplantation (NCT01430156). Two phase I trials are currently recruiting patients investigating the effect of ghrelin (GHRL) on kidney function and blood pressure in healthy volunteers (NCT02528422) as well as in a cohort of type 2 diabetes patients (NCT02913703). Apelin and kallikrein 1 (KLK1) are two other factors being investigated in the context of diabetes in phase I and phase II trials, respectively. The positive impact on renal function of brain natriuretic peptide (BNP) has been studied in two trials so far with one phase II trial being registered in the clinical trial database for the prostaglandin I2 synthase (PTGIS) studying the impact on serum creatinine in a cohort of patients with primary glomerular disease.
The factor with the most clinical trials in the context of renal disease or diabetes is adrenocorticotropin, a peptide hormone derived from proopiomelanocortin. It is currently approved by the FDA to treat kidney disorders associated with proteinuria. Its direct protective effects on the kidney are documented although the exact mechanisms of action are not fully understood.
The fact that the drug development process is always a two-edged sword with positive therapeutic effects as well as unwanted adverse effect was exemplified by bardoxolone, an activator of the renoprotective factor NRF2 and repressor of NFKB. The clinical stage III BEACON trial had to be terminated due to a higher rate of cardiovascular events in the treatment arm as compared to the placebo group after showing very promising results on renal function measured as eGFR in a preceding phase II trial. 28, 29 Patient stratification might lead to a more positive benefit/ risk ratio for bardoxolone methyl, which is the current research focus of newly initiated clinical trials. 30 Natural compounds capable of activating NRF2 such as resveratrol or curcumin with a better side effect profile pose promising therapeutic options counterbalancing renal dysfunction. 27 Computational network-based modelling approaches and Ongoing and completed clinical trials studying the effect of a renoprotective factor in the context of renal disease or diabetes.
pharmacogenomics analyses have shown promise in the past to decipher drug mechanism of action on a molecular level as well as to estimate adverse side effects. 74, 75 Despite its dose-dependent nephrotoxic potential, tacrolimus, for example, was also reported to have positive effects due to its anti-inflammatory properties on patients with diabetic nephropathies. 76 Biomarkers reflecting deregulated mechanisms on a molecular level linked to drug mechanism of action might indicate which patients have the best benefit to risk ratio. 77 Finally, drugs tested in other therapeutic areas modulating expression of renoprotective factors might enter the field of nephrology via the route of drug repositioning.
| CONCLUSIONS
We have created a set of 193 nephroprotective factors based on the information from GeneRIFs which was investigated regarding involvement in biological processes as well as tissue-specific expression. A subset of these factors either is targeted by drugs in clinical trials in the context of renal disease or diabetes or itself is used as investigational compound in one of these trials. This set serves as a starting point for further investigations using these factors as markers, targets or drugs themselves in the context of renal diseases.
